SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
ISIS Analysis & Videos »
ISIS: Bull or Bear?
ISIS - Last Tuesday's Drop Presents a Nice Buy Opportunity
ISIS
|
|
|
-4.76%
in
11 days
<> Shares of Isis Pharmaceuticals ( ISIS ) dropped about 17% on Tuesday, November 17 to close at $11.12, down from a previous close of $13.40. The selloff was a reaction to Isis and partner Genzyme( GENZ )'s presentation for Mipomersen Phase 3 Trials data for treatment of HoFH during at the American Heart Association's scientific sessions the same day. The results of the study appear very promising, with a 25 percent reduction in LDL-cholesterol after 26 weeks of treatment, vs. 3 percent for placebo patients. In fact, some patients even showed a "very impressive" 70 percent or 80 percent ...
|
FDA, Clinical Trial Calendar Updates: WYE, SVNT, AMRN, ISIS, SLXP, SOMX
ISIS
|
|
|
-29.60%
in
212 days
<> Below is a summary of updates to the <font> BioMedReports.com </font> database of over 200 entries included in the <font> FDA and Clinical Trial Calendars </font> . The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA fo...
|
FDA, Clinical Trial Calendar Updates: Genzyme, Isis, Osiris, Roche, Watson
ISIS
|
|
|
-5.99%
in
15 days
(closed on 05/07/09)
<> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA for complete r...
|
Top 40 Rated Emerging Bio-Pharma Stocks
ISIS
|
|
|
+17.78%
in
120 days
(closed on 04/22/09)
<> 
The accompanying table [click to enlarge] highlights the Top 40 Rated stocks (sorted alphabetically) in the ETF Innovators [ETFI] Emerging Bio-Pharma Index of biotech and pharmaceutical companies with market caps of $200M-$1.5B. The rating system factors in each company's number of innovative clinical pipeline + marketed products, market cap weighting, and historical stock price return.
The Emerging Bio-Pharma Index has outpaced benchmark ETFs such as iShares Nasdaq Biotech (IBB), PowerShares Dynamic Pharma (PJP),...
|
A New Index of Emerging Biotech & Pharma Companies
ISIS
|
|
|
+25.67%
in
30 days
(closed on 12/22/08)
<> 
<>
The accompanying table includes the Top 40 rated companies in the ETF Innovators [ETFI] Emerging Bio-Pharma Index, which includes U.S.-listed companies with market caps between $150M-$1.5B and factors in each companies approved products, late-stage clinical pipeline, trailing 52-week stock price performance, and market cap weighting to calculate a stock rating.
The index has performed much better than its peers over the past year for both the Top 40 Rated (-9%) and all 76 companies (-15%) – doing bett< />< /><><>< />< /><>...
|
Who's Next in the Biotech Buyout Frenzy?
ISIS
|
|
|
-15.06%
in
40 days
(closed on 11/22/08)
<> The biotech industry is rapidly consolidating as big pharma companies put their cash stash to use in deals ranging from well-known large caps all the way down to unknown micro-caps in an effort to bolster their range of marketed products, late stage pipeline candidates, and drug discovery technology platforms.
Genentech (DNA) has rejected Roche's (RHHBY) $89 bid to acquire the remaining 44% of DNA it does not already own as insufficient. I think DNA could easily get $100 per share based on Eli Lilly's (LLY) $70 buyout of ImClo...
|
ISIS Pharmaceuticals Inc.
ISIS
|
|
|
-23.23%
in
523 days
<> Isis Pharmaceuticals, Inc., a biopharmaceutical company, engages in RNA-based drug discovery and development for its product pipeline and for its partners. The company’s drug development programs are focused on treating cardiovascular and metabolic diseases, as well as cancer, and inflammatory and other diseases. It primarily offers an antisense drug, Vitravene, to treat cytomegalovirus retinitis in AIDS patients. The company and its partners have approximately 18 drugs in development, including Mipomersen (ISIS 301012) for familial hypercholesterolemia patients; ISIS 113715 for type 2 dia<><><><><><><>< /><><><><><><><><><><>< /><><><><><><><><><><><><><><><><><><><><><><><><><>< />< /><><><><><><><><><><><>< />< /><><><><><><><><><><><>< />< /><><><><><><><><><><><>< />< />...
|
Isis Pharmaceuticals' Obesity Buster an Enormous Finding
ISIS
-23.12%
in
525 days
Logic may dictate that Isis Pharmaceuticals' largest multibillion-dollar blockbuster drug is its anti-lipid drug Mipomersen. After all, Genzyme (GENZ) has already paid Isis 325 million dollars upfront, and is scheduled to pay an additional 1.575 billion dollars in milestone payments.
True, Mipomersen has already proven to reverse atherosclerotic plaques in the murine model at unprecedented efficacy (up to 92%). It has also been able to lower lipid levels never achieved with traditional medicines in patients afflicted with homozygous hyperlipidemea.
|
Strong Isis Pharma Outlook
ISIS
-23.94%
in
527 days
We believe that antisense technology represents an exciting and potentially revolutionary platform for developing therapeutic candidates.
|
People Bullish on ISIS
People Bearish on ISIS
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on ISIS |
|
|
|
|
uk
(-8.74% risk: moderate)
|
|
|
More Resources
|
About Isis Pharmaceuticals Inc.
- Answers.com
Despite the challenging economic environment, two leading advisors see opportunity in a biotech stock involved in developing drugs for cancer, multiple sclerosis and diabetes -- 
